Bronchiectasis is a chronic condition characterized by irreversible dilation of the airways, leading to mucus accumulation, recurrent infections, and progressive respiratory impairment. Symptoms such as persistent cough, daily sputum production, and frequent exacerbations significantly impact quality of life. Early detection is important to prevent structural worsening and to initiate tailored therapies. Diagnostic imaging, sputum cultures, and pulmonary function testing guide therapeutic choices while excluding other conditions that mimic bronchiectasis. The interplay between infection, inflammation, and impaired airway clearance drives disease progression, requiring comprehensive care strategies.
Modern bronchiectasis treatment approaches involve both pharmacologic and non-pharmacologic interventions. Long-term antibiotics are often prescribed to suppress chronic bacterial colonization, while inhaled therapies and mucolytics enhance secretion clearance. Airway clearance techniques, such as chest physiotherapy and oscillatory devices, remain cornerstones of daily management. Pulmonary rehabilitation programs can improve exercise capacity and reduce symptom burden, while vaccination protects against secondary infections. Advances in biologic agents and anti-inflammatory therapies are expanding options for patients with severe or refractory disease. By integrating routine monitoring, personalized medication regimens, and supportive rehabilitation, clinicians can help individuals with bronchiectasis achieve better symptom control, fewer exacerbations, and improved long-term respiratory outcomes.
Title : Global warming and increasing respiratory illnesses
Yazdan Mirzanejad, University of British Columbia, Canada
Title :
Saurabh Chattopadhyay, University of Kentucky, United States
Title : Risk factors for mycobacterium avium complex infections in patients with chronic obstructive pulmonary disease
Alizaman Sadigov, Medical University, United States
Title : Managing integration and interoperability in transformed pulmonology, respiratory medicine and lung health ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Oncology (PPO) to be set up via precision oncology strategy for cancer care team: Developing targeted lung cancer therapy and advancing personalized cancer care
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Advancements in pulmonology and respiratory care through the view of Personalized and Precision Medicine (PPM) and biodesign-driven translational applications
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation